Assessment of osteoprotegerin and RANKL levels and several cardiovascular risk scoring systems in acromegaly
- PMID: 37981618
- DOI: 10.1007/s42000-023-00509-8
Assessment of osteoprotegerin and RANKL levels and several cardiovascular risk scoring systems in acromegaly
Abstract
Purpose: The OPG/RANKL (osteoprotegerin/receptor activator of nuclear factor kappa-B) system, which plays a crucial role in bone metabolism, is also associated with vascular calcification. Acromegaly is characterized by excessive secretion of growth hormone and insulin-like growth factor, and studies have demonstrated an elevated risk of cardiovascular disease in individuals with acromegaly. In this study, our objective was to investigate the relationship between OPG/RANKL and various cardiovascular risk scoring systems.
Methods: We recruited 44 consecutive acromegaly patients and 41 healthy controls with a similar age and gender distribution for this study.
Results: While RANKL levels were significantly higher in the acromegaly group compared to the controls, OPG levels were not found to be significantly different between the two groups. Furthermore, within the acromegaly group, RANKL levels were significantly higher in patients with active acromegaly compared to those with controlled acromegaly. Osteoprotegerin levels showed a positive correlation with the Framingham risk score (FRS) in the acromegaly group. Linear regression analysis revealed an association of OPG with FRS (adjusted R2 value of 21.7%).
Conclusion: OPG and RANKL may serve as potential markers for assessment of cardiovascular calcification and prediction of the cardiovascular risk status in acromegalic patients.
Keywords: Acromegaly; Cardiovascular risk score; Osteoprotegerin; Receptor-activated nuclear factor kappa-B ligand.
© 2023. The Author(s), under exclusive licence to Hellenic Endocrine Society.
Similar articles
-
Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma.Horm Metab Res. 2018 Jul;50(7):562-567. doi: 10.1055/a-0630-1529. Epub 2018 Jun 12. Horm Metab Res. 2018. PMID: 29895074
-
Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.Menopause. 2014 Jul;21(7):702-10. doi: 10.1097/GME.0000000000000127. Menopause. 2014. PMID: 24473535
-
Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.J Endod. 2015 Aug;41(8):1281-7. doi: 10.1016/j.joen.2015.03.025. Epub 2015 May 5. J Endod. 2015. PMID: 25956608
-
Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease.Curr Obes Rep. 2023 Jun;12(2):147-162. doi: 10.1007/s13679-023-00505-4. Epub 2023 May 19. Curr Obes Rep. 2023. PMID: 37208545 Free PMC article. Review.
-
Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.J Mol Med (Berl). 2001 Jun;79(5-6):243-53. doi: 10.1007/s001090100226. J Mol Med (Berl). 2001. PMID: 11485016 Review.
Cited by
-
Genetics of primary hyperparathyroidism, our first Batrinos' scholar review, metabolic syndrome, and quite a bit of reproductive endocrinology: a great issue.Hormones (Athens). 2024 Mar;23(1):1-2. doi: 10.1007/s42000-023-00523-w. Hormones (Athens). 2024. PMID: 38195949 No abstract available.
-
Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly.Front Endocrinol (Lausanne). 2024 Dec 17;15:1472680. doi: 10.3389/fendo.2024.1472680. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39741885 Free PMC article.
References
-
- Zhang L, Zeng F, Jiang M, Han M, Huang B (2022) Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling. Front Cell Dev Biol 10:1005681. https://doi.org/10.3389/fcell.2022.1005681 - DOI - PubMed - PMC
-
- Monseu M, Dubois S, Boursier J, Aube C, Gagnadoux F, Leftheriotis G, Ducluzeau PH (2016) Osteoprotegerin levels are associated with liver fat and liver markers in dysmetabolic adults. Diabetes Metab 42:364–367. https://doi.org/10.1016/j.diabet.2016.02.004 - DOI - PubMed
-
- Harper E, Forde H, Davenport C, Rochfort KD, Smith D, Cummins PM (2016) Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL. Vascul Pharmacol 82:30–40. https://doi.org/10.1016/j.vph.2016.02.003 - DOI - PubMed
-
- Callegari A, Coons ML, Ricks JL, Yang HL, Gross TS, Huber P, Rosenfeld ME, Scatena M (2013) Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification. Arterioscler Thromb Vasc Biol 33:2491–2500. https://doi.org/10.1161/ATVBAHA.113.301755 - DOI - PubMed
-
- Harsha MM, Tewari S, Gupta SK, Khanna R, Kumar S, Garg N, Kapoor A, Goel PK (2021) Acromegaly: cardiovascular risk factors, cardiovascular manifestations and early vascular alterations in relation to disease activity. Indian Heart J 73:499–502. https://doi.org/10.1016/j.ihj.2021.05.005 - DOI - PubMed - PMC
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
